Symbols

CRBU

Caribou Biosciences·NASDAQ

--(--)

CRBU Profile

Caribou Biosciences, Inc.

A clinical-stage biopharmaceutical company that develops gene-editing cell therapies

Industry

Biological Technology

Established Date

Listing Date

07/23/2021

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.cariboubio.com

Security Type

Common stock

Office address

2929 7th Street, Suite 105, Berkeley, California 94710

Business

Introduction

Caribou Biosciences, Inc., was incorporated in Delaware in October 2011. The Company is a clinical-stage biopharmaceutical company focused on developing allogeneic CAR-T cell therapies for hematological malignancies using its proprietary chRDNA genome editing technology. Its lead drug candidates vispacabtagene regedleucel (vispa-cel) and CB-011 are designed to provide broad patient accessibility and rapid treatment as spot-based products.